HK1213485A1 - 促生長素抑制素-多巴胺嵌合類似物 - Google Patents
促生長素抑制素-多巴胺嵌合類似物Info
- Publication number
- HK1213485A1 HK1213485A1 HK16101501.2A HK16101501A HK1213485A1 HK 1213485 A1 HK1213485 A1 HK 1213485A1 HK 16101501 A HK16101501 A HK 16101501A HK 1213485 A1 HK1213485 A1 HK 1213485A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- somatostatin
- dopamine chimeric
- chimeric analogs
- analogs
- dopamine
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 102000005157 Somatostatin Human genes 0.000 title 1
- 108010056088 Somatostatin Proteins 0.000 title 1
- 229960003638 dopamine Drugs 0.000 title 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
- 229960000553 somatostatin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/52—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261721372P | 2012-11-01 | 2012-11-01 | |
PCT/US2013/067661 WO2014070971A2 (en) | 2012-11-01 | 2013-10-31 | Somatostatin-dopamine chimeric analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1213485A1 true HK1213485A1 (zh) | 2016-07-08 |
Family
ID=50547875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16101501.2A HK1213485A1 (zh) | 2012-11-01 | 2016-02-11 | 促生長素抑制素-多巴胺嵌合類似物 |
Country Status (18)
Country | Link |
---|---|
US (3) | US8952128B2 (zh) |
EP (1) | EP2914280B1 (zh) |
JP (2) | JP5908184B2 (zh) |
KR (1) | KR101770231B1 (zh) |
CN (1) | CN104768570B (zh) |
AR (1) | AR093327A1 (zh) |
AU (1) | AU2013337851A1 (zh) |
BR (1) | BR112015009602A2 (zh) |
CA (1) | CA2888765A1 (zh) |
EA (1) | EA038157B1 (zh) |
ES (1) | ES2663956T3 (zh) |
HK (1) | HK1213485A1 (zh) |
IL (1) | IL238080A0 (zh) |
MX (1) | MX2015005531A (zh) |
SA (1) | SA515360377B1 (zh) |
SG (1) | SG11201502486RA (zh) |
TW (1) | TWI523863B (zh) |
WO (1) | WO2014070971A2 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI523863B (zh) * | 2012-11-01 | 2016-03-01 | 艾普森藥品公司 | 體抑素-多巴胺嵌合體類似物 |
US9777039B2 (en) | 2012-11-01 | 2017-10-03 | Ipsen Pharma S.A.S. | Somatostatin analogs and dimers thereof |
CN105820215A (zh) * | 2016-05-09 | 2016-08-03 | 中国人民解放军第二军医大学 | 一种高效合成Stylissatin A天然环七肽的制备方法 |
CN112739222A (zh) * | 2018-09-14 | 2021-04-30 | 田中惠 | 抗衰老剂以及抗衰老方法 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2619488A (en) | 1952-11-25 | Method of preparing d | ||
US2589978A (en) | 1952-03-18 | Lysergyl and isolysergyl glycines | ||
AT258479B (de) | 1961-05-29 | 1967-11-27 | Farmaceutici Italia | Verfahren zur Herstellung von neuen Verbindungen aus der Klasse des D-6-Methyl- (und -1,6-Dimethyl)-8-amino-methyl-ergolins I |
FR98F (zh) | 1961-05-29 | |||
US3966941A (en) | 1970-09-23 | 1976-06-29 | Spofa United Pharmaceutical Works | Composition for preventing lactation or pregnancy in mammals and the method for using the same |
US3901894A (en) | 1974-06-06 | 1975-08-26 | Lilly Co Eli | 8-thiomethylergolines |
HU172479B (hu) | 1976-03-09 | 1978-09-28 | Gyogyszerkutato Intezet | Sposob poluchenija novykh soedinenij s ehrgolenovymi i |
US4166182A (en) | 1978-02-08 | 1979-08-28 | Eli Lilly And Company | 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds |
DD140044A1 (de) | 1978-11-08 | 1980-02-06 | Guenter Losse | Verfahren zur herstellung von lysergyl-enkephalin-derivaten |
US4526892A (en) | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
GB2103603B (en) | 1981-08-11 | 1985-04-11 | Erba Farmitalia | Ergoline derivatives |
GB2112382B (en) | 1981-11-06 | 1985-03-06 | Erba Farmitalia | Ergoline derivatives |
CH652720A5 (en) | 1983-02-16 | 1985-11-29 | Sandoz Ag | Ergoline derivatives, their preparation and use |
PH21123A (en) | 1983-04-28 | 1987-07-27 | Erba Farmitalia | Ergoline derivatives |
US4904642A (en) | 1985-09-12 | 1990-02-27 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
US4871717A (en) | 1987-01-07 | 1989-10-03 | Administrators Of The Tulane Educational Fund | Peptides |
DE3845000C2 (de) | 1987-07-10 | 1998-11-19 | Novartis Ag | Anwendung von Octreotid zur Behandlung von Brustkrebs |
GB8813339D0 (en) | 1988-06-06 | 1988-07-13 | Sandoz Ltd | Improvements in/relating to organic compounds |
US5621133A (en) | 1989-05-31 | 1997-04-15 | Deninno; Michael P. | Dopamine agonists |
US5411966A (en) | 1990-01-15 | 1995-05-02 | Schering Aktiengesellschaft | 2, 13-disubstituted ergolines, their production and use in pharmaceutical agents |
US5210194A (en) | 1990-01-25 | 1993-05-11 | Farmitalia Carlo Erba S.R.L. An Italian Body Corporate | Process for preparing ergoline derivatives |
US5043341A (en) | 1990-04-11 | 1991-08-27 | Eli Lilly And Company | N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides |
AU8427291A (en) | 1990-07-10 | 1992-02-04 | Neurogenetic Corporation | Nucleic acid sequences encoding a human dopamine d1 receptor |
WO1994014806A1 (en) | 1992-12-24 | 1994-07-07 | Farmitalia Carlo Erba S.R.L. | Serotoninergic ergoline derivatives |
EP0683793A4 (en) | 1993-01-21 | 1997-04-09 | Univ Georgia Res Found | VACCINES AND METHODS FOR THE PREVENTION AND TREATMENT OF FETUS-BASED TOXICOSIS IN HERBIVORES. |
ATE199089T1 (de) | 1993-06-23 | 2001-02-15 | Diatide Inc | Radiomarkierte somatostatin derivate zur abbildung und zur therapeutischen verwendung |
AU692506B2 (en) | 1993-11-17 | 1998-06-11 | Ibah, Inc. | Transparent liquid for encapsulated drug delivery |
AU2582197A (en) | 1996-03-15 | 1997-10-01 | Start Technology Partnership | Methods and compositions for diagnosis and treatment of pathological conditions related to abnormal dopamine receptor expression |
AU3215597A (en) | 1996-08-30 | 1998-03-19 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
US5925618A (en) | 1997-03-06 | 1999-07-20 | American Cyanamid Company | Peptides useful as somatostatin antagonists |
GB9711043D0 (en) | 1997-05-29 | 1997-07-23 | Ciba Geigy Ag | Organic compounds |
WO1999022735A1 (en) | 1997-10-30 | 1999-05-14 | Merck & Co., Inc. | Somatostatin agonists |
DE19832191A1 (de) | 1998-07-17 | 2000-01-27 | Knoell Hans Forschung Ev | Neuartige Ergolinamin-Derivate und ihre Verwendung |
WO2000004916A1 (en) | 1998-07-23 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Encapsulation of water soluble peptides |
US6465613B1 (en) | 1998-11-19 | 2002-10-15 | Tulane University | Hydrophilic somatostatin analogs |
US6765010B2 (en) * | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US20060034937A1 (en) | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
WO2002010215A1 (en) | 2000-07-31 | 2002-02-07 | Dabur Research Foundation | Somatostatin analogs for the treatment of cancer |
WO2002085902A1 (en) | 2001-04-16 | 2002-10-31 | Finetech Laboratories Ltd. | Process and intermediates for production of cabergoline and related compounds |
CN1514843A (zh) | 2001-06-08 | 2004-07-21 | �о���Ӧ�ÿ�ѧЭ��ɷ�����˾ | 生长激素释放抑制因子-多巴胺嵌合类似物 |
EP1283216A1 (en) | 2001-08-10 | 2003-02-12 | Mallinckrodt Inc. | Somatostatin analogues binding to all somatostatin receptor subtypes and their use |
HUP0501192A3 (en) | 2001-08-23 | 2006-06-28 | Lilly Co Eli | Glucagon-like peptide-1 analogs |
GB0300095D0 (en) | 2003-01-03 | 2003-02-05 | Novartis Ag | Organic compounds |
WO2004081031A2 (en) | 2003-03-10 | 2004-09-23 | Biogen Idec Inc. | Thiol-mediated drug attachment to targeting peptides |
CA2521965A1 (en) * | 2003-04-11 | 2004-10-28 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Somatostatin-dopamine chimeric analogs |
US7329638B2 (en) | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
JP2007514752A (ja) | 2003-12-16 | 2007-06-07 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Glp−1医薬組成物 |
ATE401054T1 (de) | 2004-06-04 | 2008-08-15 | Camurus Ab | Flüssige depotformulierungen |
GB0412866D0 (en) | 2004-06-09 | 2004-07-14 | Novartis Ag | Organic compounds |
US7402652B2 (en) | 2004-09-14 | 2008-07-22 | Miller Landon C G | Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders |
WO2007149062A2 (en) | 2005-03-14 | 2007-12-27 | Board Of Regents, The University Of Texas System | Bioactive fus1 peptides and nanoprticle-polypeptide complexes |
US20060292099A1 (en) | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
US20080039405A1 (en) | 2006-04-25 | 2008-02-14 | Croda, Inc. | Modification of percutaneous absorption of topically active materials |
FR2902101B1 (fr) | 2006-06-12 | 2012-12-28 | Scras | Peptides a activite anti-proliferative |
US7862825B2 (en) | 2007-02-21 | 2011-01-04 | Mladen Vranic | Method of controlling tight blood glucose by somatostatin receptor antagonists |
CN102088998A (zh) | 2008-05-14 | 2011-06-08 | 益普生制药股份有限公司 | 生长激素释放抑制因子-多巴胺缀合物的药物组合物 |
EP2168983A1 (fr) | 2008-09-30 | 2010-03-31 | Ipsen Pharma | Nouveaux composés octapeptidiques et leur utilisation thérapeutique |
WO2010096175A1 (en) | 2009-02-20 | 2010-08-26 | Ipsen Pharma S.A.S. | Cytotoxic conjugates having neuropeptide y receptor binding compound |
WO2011104627A1 (en) | 2010-02-24 | 2011-09-01 | Ipsen Pharma S.A.S. | Metabolites of dop2-d-lys(dop2)-cyclo[cys-tyr-d-trp-lys-abu-cys]-thr-nh2 |
BR112012023303A2 (pt) | 2010-03-15 | 2020-08-25 | Ipsen Pharma S.A.S. | composição farmacêutica de ligantes do receptor do secretagogo do hormônio de crescimento. |
US9777039B2 (en) | 2012-11-01 | 2017-10-03 | Ipsen Pharma S.A.S. | Somatostatin analogs and dimers thereof |
TWI523863B (zh) | 2012-11-01 | 2016-03-01 | 艾普森藥品公司 | 體抑素-多巴胺嵌合體類似物 |
-
2013
- 2013-10-30 TW TW102139290A patent/TWI523863B/zh not_active IP Right Cessation
- 2013-10-31 EA EA201590841A patent/EA038157B1/ru unknown
- 2013-10-31 SG SG11201502486RA patent/SG11201502486RA/en unknown
- 2013-10-31 ES ES13851845.1T patent/ES2663956T3/es active Active
- 2013-10-31 CA CA2888765A patent/CA2888765A1/en not_active Abandoned
- 2013-10-31 KR KR1020157012881A patent/KR101770231B1/ko active IP Right Grant
- 2013-10-31 BR BR112015009602A patent/BR112015009602A2/pt active Search and Examination
- 2013-10-31 JP JP2015540761A patent/JP5908184B2/ja not_active Expired - Fee Related
- 2013-10-31 CN CN201380057080.8A patent/CN104768570B/zh not_active Expired - Fee Related
- 2013-10-31 EP EP13851845.1A patent/EP2914280B1/en not_active Not-in-force
- 2013-10-31 WO PCT/US2013/067661 patent/WO2014070971A2/en active Application Filing
- 2013-10-31 AU AU2013337851A patent/AU2013337851A1/en not_active Abandoned
- 2013-10-31 US US14/068,286 patent/US8952128B2/en not_active Expired - Fee Related
- 2013-10-31 US US14/439,162 patent/US9731027B2/en active Active
- 2013-10-31 MX MX2015005531A patent/MX2015005531A/es unknown
- 2013-11-01 AR ARP130104001A patent/AR093327A1/es unknown
-
2015
- 2015-02-05 US US14/614,458 patent/US9603942B2/en active Active
- 2015-04-01 IL IL238080A patent/IL238080A0/en unknown
- 2015-04-30 SA SA515360377A patent/SA515360377B1/ar unknown
-
2016
- 2016-02-11 HK HK16101501.2A patent/HK1213485A1/zh not_active IP Right Cessation
- 2016-03-16 JP JP2016051880A patent/JP2016166206A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2013337851A1 (en) | 2015-04-23 |
BR112015009602A2 (pt) | 2017-11-14 |
EA038157B1 (ru) | 2021-07-15 |
JP2015535286A (ja) | 2015-12-10 |
US20150290330A1 (en) | 2015-10-15 |
EP2914280B1 (en) | 2018-01-03 |
US20150148522A1 (en) | 2015-05-28 |
WO2014070971A2 (en) | 2014-05-08 |
JP2016166206A (ja) | 2016-09-15 |
US9731027B2 (en) | 2017-08-15 |
EP2914280A2 (en) | 2015-09-09 |
KR20150076195A (ko) | 2015-07-06 |
EP2914280A4 (en) | 2016-04-27 |
US9603942B2 (en) | 2017-03-28 |
IL238080A0 (en) | 2015-05-31 |
KR101770231B1 (ko) | 2017-08-23 |
MX2015005531A (es) | 2015-07-17 |
TW201422636A (zh) | 2014-06-16 |
CN104768570A (zh) | 2015-07-08 |
ES2663956T3 (es) | 2018-04-17 |
EA201590841A1 (ru) | 2015-12-30 |
TWI523863B (zh) | 2016-03-01 |
WO2014070971A3 (en) | 2014-07-03 |
AR093327A1 (es) | 2015-06-03 |
US8952128B2 (en) | 2015-02-10 |
JP5908184B2 (ja) | 2016-04-26 |
CA2888765A1 (en) | 2014-05-08 |
SA515360377B1 (ar) | 2016-10-10 |
SG11201502486RA (en) | 2015-04-29 |
US20140121354A1 (en) | 2014-05-01 |
CN104768570B (zh) | 2017-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1217946A1 (zh) | 司普力西歐他汀類似物 | |
IL266700B (en) | expression sequences | |
AP2014007810A0 (en) | Imidazopyrrolidinone compounds | |
EP2895078A4 (en) | SLEEVE FOR REMOVING AN ELECTRODE | |
EP2925129A4 (en) | PRO-NEUROGENIC COMPOUNDS | |
GB201209138D0 (en) | Compounds | |
GB201214750D0 (en) | Compounds | |
GB201215357D0 (en) | Compounds | |
EP2887803A4 (en) | PRO-NEUROGENIC COMPOUNDS | |
ZA201309245B (en) | Novel fluoroergoline analogs | |
EP2828262A4 (en) | IMIDAZOTRIAZINONVERBINDUNGEN | |
GB201204985D0 (en) | Compounds | |
GB201204125D0 (en) | Compounds | |
HK1213485A1 (zh) | 促生長素抑制素-多巴胺嵌合類似物 | |
GB201209096D0 (en) | Compounds | |
EP2931693A4 (en) | PARTIALLY FLUORINATED COMPOUNDS | |
GB201217310D0 (en) | Compounds | |
HK1213486A1 (zh) | 促生長素抑制素類似物及其二聚體 | |
IL228985A0 (en) | Diazonamide analogs | |
GB201210458D0 (en) | Head suppport | |
GB201223344D0 (en) | Brush mechanism | |
GB201217290D0 (en) | Compounds | |
GB201217311D0 (en) | Compounds | |
GB201215284D0 (en) | Compounds | |
GB201214250D0 (en) | Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20221103 |